Repeating the TH287 and TH588 treatments at a lower dose of 3 μM, which does not induce tubulin polymerisation defects [30], and over a longer time period may more specifically assess the consequences of TH287/TH588-induced MTH1 inhibition on NSCLC cells. Here, NUDT1 is linked to non-small cell lung carcinoma.